July 21, 2026

U-M Pathology Researcher Sriram Venneti, MD, PhD featured in NYT

U-M neuropathologist Sriram Venneti, MD, PhD, was recently featured in The New York Times for his research on diffuse midline glioma (DMG), one of the deadliest pediatric brain cancers. The national feature highlights how his work has helped transform scientists' understanding of the disease and paved the way for new treatment options that are offering hope to children and families worldwide.

All News Scientific and Clinical Research
July 10, 2026

Cyclosporiasis Cases Increase in Southeast Michigan: Testing Guidance for MLabs Clinicians

The Michigan Department of Health and Human Services (MDHHS) and local health departments are investigating a recent increase in cyclosporiasis cases, primarily affecting Southeast Michigan counties along the Ohio border. Cyclosporiasis cases typically increase during the summer months; however, the current increase is above expected seasonal incidence. Investigations are underway to identify a potential common exposure or source.

All News General News
June 17, 2026

David Manthei, MD, PhD, Named Associate Clinical Pathology Director

By Lynn McCain When Dr. David Manthei talks about his work, one theme comes up again and again: connection. Whether he is bringing together laboratory teams, mentoring residents, or collaborating with clinicians across disciplines, his focus is on strengthening relationships that ultimately improve patient care. Named Associate Director of the Clinical Pathology Division on March 1, 2026, Manthei brings a broad perspective shaped by his many roles. He serves as Section Director of Immunology and Special Chemistry, Associate Program Director for the Pathology Residency Program, Program Director

All News General News
May 19, 2026

Dr. Sara Varadarajan: Finding Balance at the Cellular Frontier

When Dr. Sara Varadarajan stepped into her new faculty role on April 1, it marked a professional milestone in her scientific journey. Her path has been shaped by curiosity, resilience, and a deep commitment to understanding how tissues heal and restore balance after injury. Most recently, Varadarajan received a prestigious NIH K99/R00 Pathway to Independence Award from the National Institute of Allergy and Infectious Diseases (NIAID).

May 13, 2026

Where Chemistry Meets Biology: Dr. Amol Mhetre’s Work in Translational Pathology

By Lynn McCain From a young age in India, Amol Mhetre, PhD, was fascinated by organic chemistry, not just as a subject but as a way to understand how molecules behave in real biological systems and to develop new therapeutics to treat disease. That curiosity has carried him across continents and into a career at the interface of chemistry, biology, and translational drug discovery. In March 2026, Mhetre was promoted to Research Investigator in the University of Michigan Department of Pathology, where his work focuses on the design and synthesis of novel small‑molecule inhibitors with

All News General News
April 8, 2026

Michigan Researchers Uncover How a 'Frankenstein' Gene Fuels Aggressive Childhood Cancer

By Anastazia Hartman Researchers in the Parolia Lab at the University of Michigan have uncovered how a single genetic event can make Ewing sarcoma—a rare and aggressive bone and soft tissue cancer that primarily affects children and young adults—more dangerous. Their findings reveal that when a gene called STAG2 is lost, the core cancer-driving protein EWS-FLI1 is redirected toward powerful genetic “on switches” that dramatically boost tumor-promoting genes. Ewing sarcomas arise from a genetic accident causing a fusion between two independent genes, EWSR1 and FLI1. When parts of these genes

All News General News Scientific and Clinical Research
April 7, 2026

From Health Lab: Researchers identify new therapeutic target for neuroendocrine tumors in the gastrointestinal tract

By Anastazia Hartman Researchers identify new therapeutic target for neuroendocrine tumors in the gastrointestinal tract Targeting two separate pathways that control lipid synthesis led to longer survival in mouse models By Ananya Sen Neuroendocrine cells are unique in their ability to act both as nerve cells and hormone-making cells. They're scattered throughout the body, including the stomach, intestines, pancreas and lungs. Tumors that arise from these cells are called neuroendocrine tumors and are often rare and slow growing. Around 70% of all neuroendocrine tumors arise in the pancreas or

All News General News Scientific and Clinical Research
March 31, 2026

Vascular STING activation facilitates NK cell anti-tumor immunity in small cell lung cancer

By Anastazia Hartman Small cell lung cancer (SCLC) is an aggressive form of lung cancer, in part because many tumors evade the immune system. SCLC does this by shutting down MHC-I, a molecule that normally acts like a “red flag” to alert T cells to recognize and attack cancer cells. Ironically, this should make SCLC vulnerable to another type of immune cell, natural killer (NK) cells, which are designed to detect and destroy cells that lack MHC-I. NK cells can kill SCLC cells in laboratory settings; however, in SCLC patients, NK cells are largely absent from the tumor environment. Navin R

All News Scientific and Clinical Research